A new regulatory board for a comprehensive health research

According to the Academy of Medical Sciences in the UK, there is a need to have a regulatory body for health research. The authors of this plan describe the prevalent system as a disaster since they are stifling the advances in medical research. The clinical research in the UK has generally downsized and many are blaming red tape for such occurrences. According to Andrew Lansely, England's health secretary, the government will look into how these recommendations can be actualized. The aim of the report is to create a research agency for health that could make the approval of researches a lot cheaper and faster than the current system.

The clinical trials in the UK are lagging behind other countries. At around year 2000, the numbers of UK participants that take part in clinical trials are about 6%. After 6 years, the number is downsized to half of that number. The report was written by Sir Michael Rowlins, a professor and he states that the red tape is to blame to this dwindling participation of UK in the clinical trials. In the UK, it has become so much harder to initiate a research based on health due to the regulations. According to the report, the current regulatory body jeopardizes the health research in the country and this has lead to burdensome and complex issues for those in the R&D.

According to Peter Johnson, a professor who is also a member of the Cancer Research UK, it takes close to 2 years between the rewarding of the grant for research and the having a participant for a trial. The report that was passed makes a conclusion that there is a necessity for a one stop shop that can help in making faster process in making grants for the researches that could help the medical industry. This agency that they are suggesting wills e the only one that can offer an ethical approval. Included would be the National Research Governance service that will conduct the checks.

The agency will be able to easily incorporate the various services and other agencies in order to create speedier and more comprehensive approvals. The experts are hoping that with this agency, the processing time it could take grants to be processed will be cut back so that there will be less time to apply to the first patient who will be taking part of the trial. In cancer research, time is an essential aspect and this means the comprehensive agency will be able to provide grants that will not take 2 years and will only take a few months.

The problem with the current regulatory body is that it is too much complex and very discombobulated across. The government will consider this report and will find a way as to how the plan can be implemented. This agency will certainly work if the approvals have become more integrated to work for the whole UK in order to move forward and develop more studies especially for rare diseases.